Tuscan Ridge Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tuscan Ridge Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-13,400	Closed	-$2.27M	–	575
2019 Q3	$2.27M	Sell	13,400 -300	-2%	-$53.1K	0.13%	250
2019 Q2	$2.51M	Sell	13,700 -10,800	-44%	-$1.89M	0.2%	158
2019 Q1	$4.51M	Buy	24,500 +13,500	+123%	+$2.49M	0.33%	79
2018 Q4	$1.82M	Buy	+11,000	New	+$1.91M	0.18%	154

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Tuscan Ridge Asset Management's VRTX Position: Q1 2019 in Review

Tuscan Ridge Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2019, closing a stake of 6,990 shares — an estimated $1.29M sold.

Tuscan Ridge Asset Management first reported a position in VRTX in Q4 2018 and held it in 1 quarter. The position peaked at $1.16M in Q4 2018. 736 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

Tuscan Ridge Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Tuscan Ridge Asset Management sold 6,990 Vertex Pharmaceuticals shares in Q1 2019, an estimated $1.29M.
Tuscan Ridge Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Tuscan Ridge Asset Management's Vertex Pharmaceuticals position peaked at $1.16M in Q4 2018.
736 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on Tuscan Ridge Asset Management's 13F filing for Q1 2019, filed 15 May 2019.